HTH(HTH)
HTH
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $1.26B | $1.30B |
| Low | $1.24B | $1.29B |
| High | $1.28B | $1.31B |
| EBITDA Avg | $201M | $206M |
| Low | $198M | $205M |
| High | $204M | $208M |
| EBIT Avg | $182M | $187M |
| Low | $179M | $186M |
| High | $185M | $189M |
| Net Income Avg | $146M | $154M |
| Low | $138M | $146M |
| High | $187M | $163M |
| EPS Avg | $2.53 | $2.46 |
| Low | $2.20 | $2.32 |
| High | $2.98 | $2.60 |
| Analysts (Rev / EPS) | 3 / 3 | 3 / 3 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $321M | $321M | $303M | $324M | $338M | $330M |
| Low | $318M | $311M | $298M | $318M | $332M | $324M |
| High | $324M | $334M | $312M | $334M | $348M | $340M |
| EBITDA Avg | $51M | $51M | $48M | $52M | $54M | $53M |
| Low | $51M | $49M | $47M | $51M | $53M | $52M |
| High | $52M | $53M | $50M | $53M | $55M | $54M |
| EBIT Avg | $46M | $46M | $44M | $47M | $49M | $48M |
| Low | $46M | $45M | $43M | $46M | $48M | $47M |
| High | $47M | $48M | $45M | $48M | $50M | $49M |
| Net Income Avg | $37M | $37M | $27M | $32M | $44M | $40M |
| Low | $33M | $30M | $26M | $31M | $43M | $39M |
| High | $43M | $50M | $28M | $33M | $45M | $41M |
| EPS Avg | $0.63 | $0.63 | $0.47 | $0.55 | $0.76 | $0.68 |
| Low | $0.56 | $0.51 | $0.45 | $0.54 | $0.74 | $0.67 |
| High | $0.74 | $0.86 | $0.48 | $0.57 | $0.78 | $0.71 |
| Analysts (Rev / EPS) | 3 / 3 | 3 / 3 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |